NISCAIR Online Periodicals Repository

NISCAIR ONLINE PERIODICALS REPOSITORY (NOPR)  >
NISCAIR PUBLICATIONS >
Research Journals >
Indian Journal of Experimental Biology (IJEB) >
IJEB Vol.50 [2012] >
IJEB Vol.50(05) [May 2012] >


Title: Nimodipine down-regulates CGRP expression in the rat trigeminal nucleus caudalis
Authors: Vijayan, Lakshmy
Bansal, Devanshu
Ray, Subrata Basu
Keywords: Calcium channel blocker
cAMP response-element binding protein
Image J
Immunohistochemistry
Migraine
Trigeminal ganglia
Issue Date: May-2012
Publisher: NISCAIR-CSIR, India
Abstract: L-type calcium channel blockers like verapamil are used in the prophylaxis of migraine. However, their effect on the expression of CGRP in the trigeminal nucleus caudalis (TNC) is unknown. It is important because an earlier study had shown that olcegepant, a CGRP receptor antagonist, acts at the level of the trigeminal spinal nucleus rather than the trigeminal ganglia. Nimodipine was used in the present study as it crosses the blood-brain barrier. The objective of the study was to determine the pattern of expression of calcitonin gene-related peptide (CGRP) in the TNC after administration of nimodipine and/or morphine. Wistar rats were injected with saline, morphine, nimodipine or morphine + nimodipine for 14 days. Subsequently, the lowest part of the medulla oblongata containing the spinal nucleus was removed and processed for immunohistochemical localization of CGRP. The density of expression was quantified using Image J software. The results were statistically analyzed. CGRP expression was noted over the superficial part of the TNC, which decreased significantly after nimodipine administration. Conversely, morphine produced an up-regulation. The expression was unchanged with reference to saline in the morphine + nimodipine treated group. Decreased expression of CGRP in the trigeminal nucleus caudalis after nimodipine is being reported for the first time. Also, whether CGRP expression can be used as a marker for predicting the therapeutic efficacy of an anti-migraine drug is currently being investigated.
Page(s): 320-324
CC License:  CC Attribution-Noncommercial-No Derivative Works 2.5 India
ISSN: 0975-1009 (Online); 0019-5189 (Print)
Source:IJEB Vol.50(05) [May 2012]

Files in This Item:

File Description SizeFormat
IJEB 50(5) 320-324.pdf148.19 kBAdobe PDFView/Open
 Current Page Visits: 539 
Recommend this item

 

National Knowledge Resources Consortium |  NISCAIR Website |  Contact us |  Feedback

Disclaimer: NISCAIR assumes no responsibility for the statements and opinions advanced by contributors. The editorial staff in its work of examining papers received for publication is helped, in an honorary capacity, by many distinguished engineers and scientists.

CC License Except where otherwise noted, the Articles on this site are licensed under Creative Commons License: CC Attribution-Noncommercial-No Derivative Works 2.5 India

Copyright © 2012 The Council of Scientific and Industrial Research, New Delhi. All rights reserved.

Powered by DSpace Copyright © 2002-2007 MIT and Hewlett-Packard | Compliant to OAI-PMH V 2.0

Home Page Total Visits: 586901 since 06-Feb-2009  Last updated on 18-Sep-2014Webmaster: nopr@niscair.res.in